

# Shinichi Sasaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3476456/publications.pdf>

Version: 2024-02-01

26  
papers

443  
citations

840776

11  
h-index

752698

20  
g-index

26  
all docs

26  
docs citations

26  
times ranked

812  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor- $\beta$ 1. <i>Respiratory Research</i> , 2019, 20, 119.	3.6	74
2	Japanese guideline for the treatment of idiopathic pulmonary fibrosis. <i>Respiratory Investigation</i> , 2018, 56, 268-291.	1.8	72
3	Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. <i>Respiratory Investigation</i> , 2016, 54, 14-19.	1.8	51
4	Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 125-132.	2.1	45
5	Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. <i>Future Oncology</i> , 2019, 15, 1911-1920.	2.4	36
6	Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. <i>European Respiratory Journal</i> , 2021, 57, 2000348.	6.7	31
7	Dasatinib Suppresses TGF $\beta$ 2-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis. <i>Lung</i> , 2018, 196, 531-541.	3.3	18
8	Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. <i>Internal Medicine</i> , 2019, 58, 3283-3287.	0.7	17
9	Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF- $\beta$ /Smad pathway. <i>Respiratory Investigation</i> , 2020, 58, 275-284.	1.8	17
10	Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review. <i>Oncotarget</i> , 2018, 9, 24000-24013.	1.8	17
11	Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1506-1513.	3.9	14
12	Management of skin sarcoidosis with minocycline monotherapy. <i>Respirology Case Reports</i> , 2019, 7, e00413.	0.6	9
13	Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib. <i>Thoracic Cancer</i> , 2021, 12, 1536-1548.	1.9	9
14	Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1495-1505.	3.9	8
15	A Case of a Pregnant Woman Diagnosed as Having ALK-rearranged Lung Adenocarcinoma. <i>In Vivo</i> , 2018, 32, 1205-1209.	1.3	5
16	Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa068.	0.7	5
17	Development of interstitial pneumonia during treatment with eribulin: a case report. <i>BMC Research Notes</i> , 2017, 10, 557.	1.4	4
18	Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors for fatal outcome. <i>Journal of Clinical Oncology</i> , 2017, 35, 9077-9077.	1.6	4

#	ARTICLE	IF	CITATIONS
19	CT Guided Needle Biopsy of Peripheral Lesions—Lesion Characteristics That May Increase the Diagnostic Yield and Reduce the Complication Rate. <i>Journal of Clinical Medicine</i> , 2021, 10, 2031.	2.4	3
20	Loxoprofen-induced interstitial pneumonia: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 128.	0.8	2
21	Late i.v. steroid treatment for severe COVID-19-induced acute respiratory distress syndrome: a case report. <i>Acute Medicine &amp; Surgery</i> , 2020, 7, e569.	1.2	2
22	Efficacy of fexofenadine in preventing tyrosine kinase inhibitor (TKI)-induced interstitial lung disease.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18019-e18019.	1.6	0
23	A Retrospective Analysis of Prognostic Factors of Nursing and Healthcare-Associated Pneumonia. <i>Juntendo Medical Journal</i> , 2017, 63, 354-361.	0.1	0
24	Validation of PCR-Based Testing for Surveillance of Drug Resistant <i>Acinetobacter baumannii</i> (IS <i>Aba1</i> / <sup>bla</sup> OXA-51-Like) in a Pediatric Ward. <i>Juntendo Medical Journal</i> , 2018, 64, 461-467.	0.1	0
25	NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring <i>EGFR</i> mutations (EGFRm).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9110-9110.	1.6	0
26	Histopathologic Features of Immune-related Adverse Events in the Gastrointestinal Tract: A Case of Severe Acute Respiratory Syndrome Coronavirus 2 and Cytomegalovirus Infection in a Patient with Lung Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors. <i>Juntendo Medical Journal</i> , 2022, , .	0.1	0